BG107578A - Фармацевтичен състав, съдържащ циталопрам - Google Patents
Фармацевтичен състав, съдържащ циталопрам Download PDFInfo
- Publication number
- BG107578A BG107578A BG107578A BG10757803A BG107578A BG 107578 A BG107578 A BG 107578A BG 107578 A BG107578 A BG 107578A BG 10757803 A BG10757803 A BG 10757803A BG 107578 A BG107578 A BG 107578A
- Authority
- BG
- Bulgaria
- Prior art keywords
- citalopram
- crystals
- pharmaceutically acceptable
- solid dosage
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001202 | 2000-08-10 | ||
DKPA200001614 | 2000-10-27 | ||
PCT/DK2001/000520 WO2001080619A2 (en) | 2000-08-10 | 2001-07-30 | Pharmaceutical composition containing citalopram |
Publications (1)
Publication Number | Publication Date |
---|---|
BG107578A true BG107578A (bg) | 2003-09-30 |
Family
ID=26068858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG107578A BG107578A (bg) | 2000-08-10 | 2003-02-21 | Фармацевтичен състав, съдържащ циталопрам |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP1318805A2 (ja) |
JP (1) | JP2003531153A (ja) |
KR (1) | KR20030024833A (ja) |
CN (1) | CN1446089A (ja) |
AR (1) | AR030095A1 (ja) |
AT (1) | AT5744U1 (ja) |
AU (2) | AU2001100198B4 (ja) |
BE (1) | BE1013559A6 (ja) |
BG (1) | BG107578A (ja) |
BR (1) | BR0113250A (ja) |
CA (1) | CA2353693C (ja) |
CH (2) | CH694242A5 (ja) |
CZ (1) | CZ2003397A3 (ja) |
DE (2) | DE10139115A1 (ja) |
EA (1) | EA200300247A1 (ja) |
ES (1) | ES2172481B2 (ja) |
FI (1) | FI5176U1 (ja) |
FR (1) | FR2812811B1 (ja) |
GB (1) | GB2368014B (ja) |
GR (1) | GR1004193B (ja) |
HR (1) | HRP20030054A2 (ja) |
HU (1) | HUP0103071A3 (ja) |
IE (1) | IES20010693A2 (ja) |
IL (1) | IL154050A0 (ja) |
IS (1) | IS6021A (ja) |
IT (1) | ITMI20011637A1 (ja) |
MX (1) | MXPA03000837A (ja) |
NL (1) | NL1018741C1 (ja) |
NO (1) | NO20013891L (ja) |
NZ (1) | NZ523785A (ja) |
PL (1) | PL359824A1 (ja) |
SK (1) | SK2842003A3 (ja) |
WO (1) | WO2001080619A2 (ja) |
YU (1) | YU9003A (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS6021A (is) * | 2000-08-10 | 2001-10-20 | H. Lundbeck A/S | Lyfjasamsetningar sem innihalda sítalópram |
AU2001100195B4 (en) * | 2001-01-05 | 2001-12-20 | H Lundbeck As | Pharmaceutical composition containing citalopram. |
GB0206708D0 (en) * | 2002-03-21 | 2002-05-01 | Cipla Ltd | Pharmaceutical salts |
US6812355B2 (en) | 2002-10-22 | 2004-11-02 | Sekhsaria Chemicals Limited | Process for the manufacture of citalopram hydrobromide from 5-bromophthalide |
WO2004056791A1 (en) * | 2002-12-23 | 2004-07-08 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
WO2004103361A2 (en) * | 2003-05-20 | 2004-12-02 | Ranbaxy Laboratories Limited | A pharmaceutical dosage form of citalopram |
HU227491B1 (en) * | 2003-11-25 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Tablet containing citalopram hydrogen bromide |
WO2006038217A1 (en) * | 2004-10-05 | 2006-04-13 | Strides Acrolab Limited | An improved drug delivery system of citalopram hydrobromide and process for producing the same |
US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
GB2480191A (en) * | 2007-02-02 | 2011-11-09 | Ubiquisys Ltd | Determining the location of a base station |
CN106397249A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种高稳定性lcz696结晶粉末及其制备方法 |
EP4277661A1 (en) * | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1358915A (en) * | 1919-04-14 | 1920-11-16 | Amici Domenico | Aeroplane |
GB1358915A (en) * | 1971-09-13 | 1974-07-03 | Merck & Co Inc | Directly compressed tablet and composition therefor |
GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
GB9714841D0 (en) * | 1997-07-14 | 1997-09-17 | Smithkline Beecham Plc | Treatment method |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
US6977306B2 (en) | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
IS6021A (is) * | 2000-08-10 | 2001-10-20 | H. Lundbeck A/S | Lyfjasamsetningar sem innihalda sítalópram |
-
2001
- 2001-07-24 IS IS6021A patent/IS6021A/is unknown
- 2001-07-24 IE IE20010693A patent/IES20010693A2/en not_active IP Right Cessation
- 2001-07-24 CA CA002353693A patent/CA2353693C/en not_active Expired - Lifetime
- 2001-07-26 AU AU2001100198A patent/AU2001100198B4/en not_active Expired
- 2001-07-26 HU HU0103071A patent/HUP0103071A3/hu unknown
- 2001-07-27 IT IT2001MI001637A patent/ITMI20011637A1/it unknown
- 2001-07-30 KR KR10-2003-7001683A patent/KR20030024833A/ko not_active Application Discontinuation
- 2001-07-30 MX MXPA03000837A patent/MXPA03000837A/es unknown
- 2001-07-30 PL PL01359824A patent/PL359824A1/xx not_active Application Discontinuation
- 2001-07-30 NZ NZ523785A patent/NZ523785A/en unknown
- 2001-07-30 EA EA200300247A patent/EA200300247A1/ru unknown
- 2001-07-30 IL IL15405001A patent/IL154050A0/xx unknown
- 2001-07-30 BR BR0113250-4A patent/BR0113250A/pt not_active IP Right Cessation
- 2001-07-30 EP EP01957768A patent/EP1318805A2/en not_active Withdrawn
- 2001-07-30 CZ CZ2003397A patent/CZ2003397A3/cs unknown
- 2001-07-30 YU YU9003A patent/YU9003A/sh unknown
- 2001-07-30 SK SK284-2003A patent/SK2842003A3/sk not_active Application Discontinuation
- 2001-07-30 WO PCT/DK2001/000520 patent/WO2001080619A2/en not_active Application Discontinuation
- 2001-07-30 CN CN01813752A patent/CN1446089A/zh active Pending
- 2001-07-30 JP JP2001577732A patent/JP2003531153A/ja not_active Withdrawn
- 2001-07-30 AU AU2001279591A patent/AU2001279591A1/en not_active Abandoned
- 2001-07-31 AR ARP010103662A patent/AR030095A1/es not_active Application Discontinuation
- 2001-07-31 GB GB0118579A patent/GB2368014B/en not_active Expired - Fee Related
- 2001-07-31 GR GR20010100377A patent/GR1004193B/el unknown
- 2001-08-07 AT AT0062401U patent/AT5744U1/de not_active IP Right Cessation
- 2001-08-08 FR FR0110586A patent/FR2812811B1/fr not_active Expired - Fee Related
- 2001-08-08 CH CH01469/01A patent/CH694242A5/de not_active IP Right Cessation
- 2001-08-08 CH CH01422/03A patent/CH694241A5/de not_active IP Right Cessation
- 2001-08-09 DE DE10139115A patent/DE10139115A1/de not_active Ceased
- 2001-08-09 FI FI20010303U patent/FI5176U1/fi active
- 2001-08-09 NO NO20013891A patent/NO20013891L/no not_active Application Discontinuation
- 2001-08-09 ES ES200101877A patent/ES2172481B2/es not_active Expired - Fee Related
- 2001-08-09 DE DE20113195U patent/DE20113195U1/de not_active Ceased
- 2001-08-10 NL NL1018741A patent/NL1018741C1/nl not_active IP Right Cessation
- 2001-08-10 BE BE2001/0537A patent/BE1013559A6/fr not_active IP Right Cessation
-
2003
- 2003-01-27 HR HR20030054A patent/HRP20030054A2/hr not_active Application Discontinuation
- 2003-02-21 BG BG107578A patent/BG107578A/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5192568B2 (ja) | エスシタロプラムを含む結晶性組成物 | |
AU2002355624A1 (en) | Crystalline composition containing escitalopram | |
BG107578A (bg) | Фармацевтичен състав, съдържащ циталопрам | |
US20030109577A1 (en) | Pharmaceutical composition containing citalopram | |
US20030232881A1 (en) | Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them | |
ZA200300561B (en) | Pharmaceutical composition containing citalopram. | |
GB2376233A (en) | Crystals of a pharmaceutically acceptable salt of citalopram wherein the median particle size of the crystals is at least 40 microns |